An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

ClinicalTrials.gov ID: NCT07224373

Public ClinicalTrials.gov record NCT07224373. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

Study identification

NCT ID: NCT07224373
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Multiple Sclerosis

Interventions

AZD0120 - Regimen 1 Biological
AZD0120 - Regimen 2 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 8, 2025
Primary completion: Dec 11, 2028
Completion: Dec 11, 2028
Last update posted: Aug 24, 2026

2025 – 2028

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85719	Withdrawn
Research Site	Aurora	Colorado	80045	Not yet recruiting
Research Site	Washington D.C.	District of Columbia	20010	Recruiting
Research Site	St Louis	Missouri	63110	Recruiting
Research Site	New York	New York	10016	Recruiting
Research Site	New York	New York	10032	Recruiting
Research Site	Cleveland	Ohio	44195	Not yet recruiting
Research Site	Seattle	Washington	98122	Recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07224373, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2026 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07224373 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →